Details

Autor(en) / Beteiligte

• Lebwohl, Mark
• Strober, Bruce
• Menter, Alan
• Gordon, Kenneth
• Weglowska, Jolanta
• Puig, Lluis
• Papp, Kim
• Spelman, Lynda
• Toth, Darryl
• Kerdel, Francisco
• Armstrong, April W
• Stingl, Georg
• Kimball, Alexa B
• Bachelez, Herve
• Wu, Jashin J
• Crowley, Jeffrey
• Langley, Richard G
• Blicharski, Tomasz
• Paul, Carle
• Lacour, Jean-Philippe
• Tyring, Stephen
• Kircik, Leon
• Chimenti, Sergio
• Callis Duffin, Kristina
• Bagel, Jerry
• Koo, John
• Aras, Gary
• Li, Joanne
• Song, Wenjie
• Milmont, Cassandra E
• Shi, Yifei
• Erondu, Ngozi
• Klekotka, Paul
• Kotzin, Brian
• Nirula, Ajay

Titel

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Ist Teil von

• The New England journal of medicine, 2015-10, Vol.373 (14), p.1318-1328

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In two phase 3 studies, the anti–interleukin-17 receptor A monoclonal antibody brodalumab was more effective than placebo or ustekinumab in patients with moderate-to-severe psoriasis. Adverse events associated with brodalumab included neutropenia and candida infections. Psoriasis is an inflammatory skin disease that occurs in 2 to 3% of the worldwide population. 1 , 2 Despite the availability of several therapies, many patients remain untreated, do not have an adequate response, or have treatment-related toxic effects. 3 Interleukin-17 cytokines have been implicated in the pathogenesis of psoriasis. Genomewide association studies have linked interleukin-17 pathway–related genes with psoriasis, 4 , 5 and interleukin-17 mRNA levels are higher in psoriatic lesions than in normal skin. 6 , 7 Numbers of type 17 helper T cells are increased in psoriatic lesions and are stimulated by interleukin-23 to release interleukin-17 cytokines. 8 Interleukin-17 cytokines, which include interleukin-17A, interleukin-17C, . . .